{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T14:30:24Z","timestamp":1778509824489,"version":"3.51.4"},"reference-count":14,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Fundacion Pedro Jaen","award":["psoriasis research"],"award-info":[{"award-number":["psoriasis research"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Background\/Objectives: Despite substantial progress in the management of psoriasis, evidence on as-needed dosing strategies for biologic therapies remains scarce. In this context, the present study aimed to assess the effectiveness of a previously defined as-needed bimekizumab (BKZ) dosing regimen in a larger cohort of patients with psoriasis, as well as to identify clinical factors associated with treatment response. Methods: In this retrospective study, medical records of 64 patients with moderate-to-severe psoriasis treated with BKZ between May 2023 and November 2025 at a specialized psoriasis unit in Madrid, Spain, were reviewed. Patients followed an off-label, as-needed dosing regimen, consisting of two initial 320 mg doses at Weeks 0 and 4, with subsequent administrations only upon loss of a PASI 90 response. The primary outcome was the proportion of patients achieving and maintaining optimal disease control (PASI 90) over time. The duration of treatment effect was defined as the interval between the second dose and loss of PASI90 in the absence of further treatment. Safety outcomes were also evaluated. Results: A total of 59 out of 64 patients achieved a PASI 90 response after the initial two BKZ doses, and all maintained disease control with the as-needed dosing strategy over time. On average, patients received approximately one-third of the doses expected under the standard dosing regimen. The mean duration of treatment effect following the second dose was approximately 24 weeks. Systemic and bio-na\u00efve patients presented the longest treatment effect duration under the as-needed dosing regimen. Oral candidiasis was reported in two patients and resolved without complications. Conclusions: This study reinforces previous evidence supporting the effectiveness of an as-needed BKZ dosing strategy, particularly in patients na\u00efve to systemic and biologic therapies for psoriasis. Nevertheless, larger prospective studies are required to confirm these findings.<\/jats:p>","DOI":"10.3390\/jpm16050234","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T08:12:31Z","timestamp":1777363951000},"page":"234","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Evidence That As-Needed Dosing with Bimekizumab in Patients with Psoriasis Is Safe and Effective over Time"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5587-1204","authenticated-orcid":false,"given":"Carlota","family":"Abbad-Jaime De Arag\u00f3n","sequence":"first","affiliation":[{"name":"Department of Dermatology, Hospital Universitario Ram\u00f3n y Cajal, Instituto Ramon Y Cajal de Investigaci\u00f3n Sanitaria (IRYCIS), 28034 Madrid, Spain"},{"name":"Inflammatory Disease and Psoriasis Unit, Grupo Pedro Ja\u00e9n, 28006 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Davo-Mogica","sequence":"additional","affiliation":[{"name":"Inflammatory Disease and Psoriasis Unit, Grupo Pedro Ja\u00e9n, 28006 Madrid, Spain"},{"name":"Faculty of Medicine, Universidad Francisco de Vitoria, 28223 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"de la Cruz-Anaya","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario Ram\u00f3n y Cajal, Instituto Ramon Y Cajal de Investigaci\u00f3n Sanitaria (IRYCIS), 28034 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0348-5421","authenticated-orcid":false,"given":"Emilio","family":"Berna-Rico","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario Ram\u00f3n y Cajal, Instituto Ramon Y Cajal de Investigaci\u00f3n Sanitaria (IRYCIS), 28034 Madrid, Spain"},{"name":"Inflammatory Disease and Psoriasis Unit, Grupo Pedro Ja\u00e9n, 28006 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In\u00e9s","family":"D\u00edaz-Ruiz","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Universidad Francisco de Vitoria, 28223 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In\u00e9s","family":"Perales-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Department of Vascular Physiopathology, Hospital Nacional de Parapl\u00e9jicos, Servicio de Salud de Castilla-La Mancha (SESCAM), 45071 Toledo, Spain"},{"name":"Department of Vascular Physiopathology, Hospital Nacional de Parapl\u00e9jicos, Instituto de Investigaci\u00f3n Sanitaria de Castilla-La Mancha (IDISCAM), 45071 Toledo, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas D.","family":"Brownstone","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Ja\u00e9n","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario Ram\u00f3n y Cajal, Instituto Ramon Y Cajal de Investigaci\u00f3n Sanitaria (IRYCIS), 28034 Madrid, Spain"},{"name":"Inflammatory Disease and Psoriasis Unit, Grupo Pedro Ja\u00e9n, 28006 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6083-0952","authenticated-orcid":false,"given":"Lluis","family":"Puig","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Institut d\u2019Investigaci\u00f3 Biom\u00e8dica Sant Pau (IIB SANT PAU), Universitat Aut\u00f2noma de Barcelona, 08041 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2633-985X","authenticated-orcid":false,"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[{"name":"Blauvelt Consulting, LLC, Annapolis, MD 21401, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alvaro","family":"Gonz\u00e1lez-Cantero","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario Ram\u00f3n y Cajal, Instituto Ramon Y Cajal de Investigaci\u00f3n Sanitaria (IRYCIS), 28034 Madrid, Spain"},{"name":"Inflammatory Disease and Psoriasis Unit, Grupo Pedro Ja\u00e9n, 28006 Madrid, Spain"},{"name":"Faculty of Medicine, Universidad Francisco de Vitoria, 28223 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-025-00630-5","article-title":"Psoriasis","volume":"11","author":"Armstrong","year":"2025","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","first-page":"1","article-title":"Update Aetiopathogenesis and Treatment of Psoriasis: A Literature Review","volume":"4","year":"2023","journal-title":"J. Dermatol. Res."},{"key":"ref_3","first-page":"S2","article-title":"Pathogenesis and treatment of psoriasis: Exploiting pathophysiological pathways for precision medicine","volume":"33","author":"Alwan","year":"2015","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"van Riel, C.A.M., Michielsens, C.A.J., van Muijen, M.E., van der Schoot, L.S., Reek, J.M.P.A.v.D., and de Jong, E.M.G.J. (2024). Dose reduction of biologics in patients with plaque psoriasis: A review. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1369805"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1080\/14712598.2023.2244872","article-title":"Reduced doses of biological therapies in psoriasis: A new potentially \u201csustainable\u201d frontier of psoriasis treatment","volume":"23","author":"Ribero","year":"2023","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e70062","DOI":"10.1111\/exd.70062","article-title":"Dose Modulation Strategies in Psoriatic Patients: Real-Life Pilot Comparison Between Risankizumab and Guselkumab up to 12\u2009Months After Dose Spacing","volume":"34","author":"Mastorino","year":"2025","journal-title":"Exp. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jaad.2025.12.007","article-title":"Exploring reasonable extension of secukinumab dosing intervals in real-world settings","volume":"94","author":"Zhao","year":"2025","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2492197","DOI":"10.1080\/09546634.2025.2492197","article-title":"Bimekizumab as-needed dosing in patients with psoriasis: A case series","volume":"36","author":"Blauvelt","year":"2025","journal-title":"J. Dermatol. Treat."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"20406223211046685","DOI":"10.1177\/20406223211046685","article-title":"Impact of previous biologic use and body weight on the effectiveness of guselkumab in moderate-to-severe plaque psoriasis: A real-world practice","volume":"12","author":"Hung","year":"2021","journal-title":"Ther. Adv. Chronic Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): A multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial","volume":"397","author":"Gordon","year":"2021","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1001\/jamadermatol.2024.1677","article-title":"Clinical Characteristics Associated With Response to Biologics in the Treatment of Psoriasis: A Meta-analysis","volume":"160","author":"Hjort","year":"2024","journal-title":"JAMA Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Felix, P.A.O., Sampaio, A.L., Silva, B.L., and Viana, A.L.P. (2022). Early intervention in psoriasis: Where do we go from here?. Front. Med., 9.","DOI":"10.3389\/fmed.2022.1027347"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa2102388","article-title":"Bimekizumab versus Adalimumab in Plaque Psoriasis","volume":"385","author":"Warren","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","article-title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): Efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/16\/5\/234\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T13:33:25Z","timestamp":1778506405000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/16\/5\/234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":14,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["jpm16050234"],"URL":"https:\/\/doi.org\/10.3390\/jpm16050234","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]}}}